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Abstract
Background: Adjuvant therapies can prevent/delay bone metastasis development in breast cancer. We investigated whether
serum bone turnover markers in early disease have clinical utility in identifying patients with a high risk of developing bone
metastasis.
Methods: Markers of bone formation (N-terminal propeptide of type-1 collagen [P1NP]) and bone resorption (C-telopeptide of
type-1 collagen [CTX], pyridinoline cross-linked carboxy-terminal telopeptide of type-1 collagen [1-CTP]) were measured in
baseline (pretreatment blood samples from 872 patients from a large randomized trial of adjuvant zoledronic acid (AZURE-
ISRCTN79831382) in early breast cancer. Cox proportional hazards regression and cumulative incidence functions (adjusted
for factors having a statistically significant effect on outcome) were used to investigate prognostic and predictive associations
between recurrence events, bone marker levels, and clinical variables. All statistical tests were two-sided.
Results: When considered as continuous variables (log transformed), P1NP, CTX, and 1-CTP were each prognostic for future
bone recurrence at any time (P ¼ .006, P ¼ .009, P ¼ .008, respectively). Harrell’s c-indices were a P1NP of 0.57 (95% confidence
interval [CI] ¼ 0.51 to 0.63), CTX of 0.57 (95% CI¼0.51 to 0.62), and 1-CTP of 0.57 (95% CI¼0.52 to 0.63). In categorical analyses
based on the normal range, high baseline P1NP (>70 ng/mL) and CTX (>0.299 ng/mL), but not 1-CTP (>4.2 ng/mL), were also
prognostic for future bone recurrence (P ¼ .03, P ¼ .03, P ¼ .10, respectively). None of the markers were prognostic for overall
distant recurrence; that is, they were bone metastasis specific, and none of the markers were predictive of treatment benefit
from zoledronic acid.
Conclusions: Serum P1NP, CTX, and 1-CTP are clinically useful, easily measured markers that show good prognostic ability
(though low-to-moderate discrimination) for bone-specific recurrence and are worthy of further study.
More than 40 000 women die from breast cancer annually in the
United States, mainly from distant relapse, which often occurs
years after initial breast cancer diagnosis (1). Bone metastases
ultimately affect more than two-thirds of patients with ad-
vanced disease (2). Breast cancer cells can remain dormant for
many years in the bone microenvironment, escaping the effects
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of adjuvant systemic therapies and retaining the potential for
future activation and proliferation, resulting in metastasis in
bone and/or other distant sites.
Because breast cancer cells display this affinity for bone,
there is a sound rationale for targeting the bone in the adjuvant
setting. Randomized trials of adjuvant bisphosphonates, con-
firmed by a meta-analysis of all available data (n ¼ 18 766), have
indeed shown that development of bone metastases and death
from breast cancer can be reduced. However, the benefits are
confined to postmenopausal patients at the time of bisphosph-
onate initiation (3–7), strongly suggesting that the postmeno-
pausal bone (marrow) microenvironment has a specific
interaction with tumor cell homing to bone and/or tumor
dormancy.
In the AZURE trial (ISRCTN79831382) in early breast cancer,
3360 women with stage II/III breast cancer were randomized to
standard adjuvant treatment alone or with the addition of zole-
dronic acid (zoledronate, administered over five years (3,6).
With a median of 84.2 months (interquartile range [IQR] ¼ 66–93
months) of follow-up, zoledronate improved invasive disease–
free survival (IDFS) in women who were more than five years
postmenopausal at diagnosis (n ¼ 1041, adjusted hazard ratio
[HR] ¼ 0.77, 95% confidence interval [CI] ¼ 0.63 to 0.96). Baseline
(pretreatment) serum samples were collected in a subset of
patients, and these provide the opportunity for prespecified
analyses of relationships between bone metabolism, as deter-
mined by serum bone turnover markers and disease outcomes
with or without zoledronate. The role of bone turnover markers
has been extensively studied in established bone metastasis
(8,9). In the current study, our aims were to determine whether,
in early breast cancer, levels of bone turnover markers predicted
either the risk of disease relapse (both in and outside bone) or
the treatment benefits from zoledronate.
Methods
Patients
In the AZURE trial (3,6), following written informed consent,
women with histologically confirmed breast cancer and either
lymph node metastasis or T3/T4 primary tumor were randomly
assigned to either standard adjuvant therapy (control) or stan-
dard adjuvant therapy plus intravenous zoledronate 4 mg (19
doses over five years).
At UK centers, ethics approval was obtained for this study,
and participants gave additional consent for blood donation at
study entry to be used for biomarker assessment. Serum sam-
ples were collected and stored under strict standard operating
procedures temporarily at –20 C or –80 C at local centers before
regular transfer to Sheffield for storage at –80 C until central
batch analysis.
Laboratory Assays
Bone biomarkers were measured against reference standards in
a fully accredited central laboratory (Metabolic Bone Unit,
University of Sheffield) according to strict standard operating
procedures. Personnel performing and reporting the analyses
were blinded to clinical data.
Bone Biomarker Analysis
We measured two biomarkers of bone resorption, C-telopeptide
of type-1 collagen (CTX), a measure of cathepsin-K-linked
collagen breakdown, and pyridinoline cross-linked carboxy-ter-
minal telopeptide of type-1 collagen (1-CTP), which is liberated
by matrix metalloproteinases during degradation of mature
type-1 collagen. Because 1-CTP is not produced through cathep-
sin-K-mediated bone resorption, its concentration is less af-
fected by menopause (10). N-terminal propeptide of type-1
collagen (P1NP), released during collagen formation, is a robust
and reliable measure of bone formation and was selected for
this study (11). P1NP and CTX were measured using Cobas e411
automated immunoassays (Roche Diagnostic, Mannheim,
Germany), and 1-CTP was measured by manual enzyme immu-
noassay (Orion Diagnostica UniQ ICTP EIA, Espoo, Finland).
The P1NP assay has a lower detection limit of 5 ng/mL and
interassay coefficient of variation (CV) of 4.1%. Values were
categorized as “high” if greater than 70 ng/mL based on advice
from Roche Diagnostics. Results of 70 ng/mL or less were
categorized as normal. The CTX assay has a measurement
range of 0.010 to 6.00 ng/mL and an interassay CV of 4.0%. The
upper limit of normal for premenopausal women (0.299 ng/mL)
was used to categorize results as either “high” (>0.299 ng/mL) or
“normal” (0.299 ng/mL). We also performed additional analy-
ses with a higher threshold (high >0.556 ng/mL) to allow closer
comparison with an earlier study by Lipton and colleagues (12).
The 1-CTP assay was conducted manually with a lower detec-
tion limit of 0.3 ng/mL and an upper limit of normal of 4.2 ng/
mL. The intraassay CV was 8.1% at 5.6 ng/mL, and the interas-
say CV was 7.6% at 4.8 ng/mL.
Statistical Analysis
Statistical analysis (consistent with REMARK guidelines) was
performed on the final AZURE analysis datalock with a median
of 84.2 months (IQR ¼ 66–93 months) of follow-up and 966
disease-free survival events (6). All analyses were performed on
the intention-to-treat population using SAS version 9.2 or 9.4.
Hypothesis testing was performed at the two-sided 5% level.
Cumulative incidence function (CIF) curves were used to in-
vestigate time to recurrence, as defined below. The Cox propor-
tional hazards (PH) model was used to assess the relationships
between the bone biomarkers and prognosis and treatment ef-
fect with zoledronate. The proportional hazards assumption
was verified by assessing the statistical significance of the inter-
action of the relevant bone biomarker and time via an interac-
tion term within the Cox model, as well as by a manual review
of the CIF curves. Bone marker data were analyzed both as con-
tinuous variables (log transformed) and as categorical variables,
using the prespecified high vs normal cut-points for both prog-
nostic and predictive relationships.
The prespecified end points in the statistical analysis plan
were: 1) time to bone recurrence, whether or not bone was the
first recurrence (with deaths without prior bone recurrence cen-
sored in the Cox PH models and considered competing-risk
events in CIF curves); 2) time to first recurrence in bone, includ-
ing first recurrence being in bone only or concurrently with recur-
rence in another distant site (with deaths without prior
recurrence and nonbone (only) first recurrences censored in the
Cox PH models and considered competing-risk events in CIF
curves); 3) time to first distant recurrence (with deaths without
prior distant recurrence censored in the Cox PH models and con-
sidered competing-risk events in CIF curves).
Analyses were performed for all participants combined and
according to menopausal status and were adjusted for mini-
mization factors found to be statistically significant for disease
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outcomes in the main AZURE analyses (ie, lymph node involve-
ment, estrogen receptor [ER] status, tumor stage, and type/timing
of systemic therapy for each end point), as well as treatment
allocation, where this was statistically significant in the main
AZURE subgroup analyses. Analyses were also adjusted for treat-
ment allocation when assessing the interaction of biomarkers
with treatment (predictive analyses), where the interaction term
is used to test for heterogeneity between the different biomarker
levels. Exploratory analyses were carried out with a composite
P1NP/CTX biomarker, in terms of both markers high vs not both
markers high.
Harrell’s c-index was used to assess the discriminatory abil-
ity of the markers, with a value of 1 representing perfect dis-
crimination and 0.5 being no better than chance. Confidence
intervals for Harrell’s c-index were calculated as suggested by
Newson (13).
Results
Patient Demographics and Baseline Data
Serum samples from 872 UK AZURE participants (441 control
arm, 431 treatment arm) were analyzed, with a median follow-
up of 84.2 months (IQR ¼ 71.1–92.1 months). Baseline patient
demographics (age, lymph node involvement, ER, progesterone
receptor [PR], and human epidermal growth factor receptor 2
(HER2) status, menopausal status, systemic therapy, chemo-
therapy and statin use) in this test subpopulation were similar
to the overall AZURE patient population (Table 1).
Comparison of IDFS outcomes for the biomarker population
with the whole AZURE population showed that both the propor-
tions of patients with an event and the hazard ratios were simi-
lar, though the confidence intervals were wider in the
biomarker population due to the smaller number of patients.
This similarity also applied when broken down into post- and
nonpostmenopausal subgroups (Supplementary Figure 1, avail-
able online).
Baseline data for the three biomarkers (also broken down
into menopausal status) revealed that the proportion of
patients in each category who fall above the normal ranges for
P1NP, CTX, and 1-CTP for the whole population were 27.3%,
30.0%, and 50.5%, respectively (Table 2), confirming that the
data were appropriate to test the relationship between acceler-
ated baseline bone turnover and subsequent distant recurrence
events.
Bone Biomarker Prognostic Analyses
Figure 1 and Table 3 display key data for prognostic analyses in
the three prespecified recurrence categories. The proportional
hazards assumption was also investigated for each Cox propor-
tional hazards model applied in our study. The majority of
markers and end points were not close to violating this assump-
tion (ie, suggesting no difference in the effects of the markers as
time elapses). For the 1-CTP marker, the assumption was only
borderline valid, suggesting that the impact of 1-CTP may differ
as time elapses, although the Cox proportional hazards model
was still appropriate.
Bone Recurrence at Any Time
In adjusted continuous log-transformed analyses (Figure 1),
increases in all three markers were strongly associated with sta-
tistically significantly increased risk of development of bone
metastasis (P1NP: P ¼ .006; CTX: P ¼ .009; 1-CTP: P ¼ .008). In cat-
egorical analyses, P1NP greater than 70 ng/mL (P ¼ .03) and CTX
greater than 0.299 ng/mL (P ¼ .03), but not CTX greater than
0.566 ng/mL (P ¼ .12) or 1-CTP greater than 4.2 ng/mL (P ¼ .10),
were statistically significantly prognostic for recurrence in bone
at any time (Table 3). Cumulative incidence plots for categorical
analysis of time to bone metastasis at any time are shown, ex-
emplified for P1NP, in Figure 2 for both control and treatment
arms.
Taking P1NP, on the basis of the above data, as the likely
most sensitive prognostic factor, we tested the role of meno-
pausal status in P1NP analyses (data not shown). However, we
detected no statistically significant prognostic effect of P1NP
on bone recurrence in either postmenopausal or non-
postmenopausal patients, when analyzed with P1NP as either a
categorical or continuous variable.
Harrell’s c-index values (when coded as [log] continuous var-
iables) were similar for all three markers: P1NP c-index was 0.57
(95% CI ¼ 0.51 to 0.63); CTX c-index was 0.57 (95% CI ¼ 0.51 to
0.62); and 1-CTP c-index was 0.57 (95% CI ¼ 0.52 to 0.63).
First Recurrence in Bone (1/2 Concurrent Recurrence Elsewhere)
In the adjusted continuous analyses, both P1NP (P ¼ .03) and
1-CTP (P ¼ .045), appeared statistically significantly prognostic
for first recurrence in bone (Figure 1, Table 3). However, in ad-
justed categorical analyses, although the hazard ratios for each
marker were similar to bone recurrence at any time, the 95%
confidence intervals were wide, and no statistically significant
relationships between higher marker values and first disease
recurrence in bone were seen. The number of bone-only first re-
currence events was too small to justify separate analysis of
this potential end point of interest.
First Distant Recurrence (Whatever the Site)
There were no associations in either continuous or categorical
analyses between baseline P1NP, CTX, or 1-CTP and develop-
ment of distant recurrence at any site (Figure 1, Table 3), clearly
demonstrating that, in contrast to recurrence specifically in
bone, the markers were not prognostic for distant metastasis
taken as a whole. Categorical data for IDFS were statistically
nonsignificant.
Composite P1NP and CTX Biomarker Analysis
Adjusted analyses were performed to assess risks of recurrence
for patients where both P1NP and CTX (using the 0.299 ng/mL
cut-point) were high compared with all other patients; details
are displayed in Table 4. No statistically significant relation-
ships were identified between the composite marker and subse-
quent recurrence, although there was an increased risk for bone
recurrence at any time in the patients with elevation of both
biomarkers (HR ¼ 1.60, 95% CI ¼ 0.99 to 2.48, P ¼ .06).
Consideration was given to a joint Cox model containing all
three markers, but there were insufficient events to make this
meaningful. Further, 1-CTP levels represent a different aspect of
the bone turnover process than P1NP and CTX and are largely
unaffected by inhibitors of osteoclast function such as
bisphosphonates (10).
Sensitivity Analyses Assessing Optimum Cut-Points
We explored the effects of different cut-points for categorical
prognostic analysis of P1NP and bone metastasis at any time.
This analysis (Figure 3) showed that the optimal cut-point for
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P1NP was approximately 64 nmol/mL, which we judged was
sufficiently close to the prespecified value of 70 nmol/mL, bear-
ing in mind that the number of events was not sufficient to gen-
erate a smooth relationship. For 1-CTP and CTX, similar
exploration yielded no clearly optimal cut-point or improve-
ment to those preselected (Supplementary Figures 2 and 3,
available online).
Analyses for Treatment Effect—Test for Predictive
Biomarkers
Although P1NP is higher in postmenopausal women and the
benefits of zoledronate are largely restricted to this subset of
patients (6,7), baseline P1NP did not predict benefit from zoledr-
onate when assessed against bone metastasis at any time out-
come. For example, in categorical analyses considering the
effect of P1NP on bone recurrence at any time, there were no
statistically significant differences in outcome between the
zoledronate and control arms for either high P1NP (HR ¼ 0.99,
95% CI ¼ 0.52 to 1.90) or normal P1NP (HR ¼ 0.84, 95% CI ¼ 0.52
to 1.37) with a nonsignificant Pinteraction value for the interaction
of P1NP and treatment (P ¼ .69) (Figure 1B).
We also found no statistically significant interaction with
treatment allocation for either of the other defined, less
frequent outcome categories with any of the bone markers, or
with the P1NP/CTX composite bone marker. However, consider-
ing the complex inter-relationships between treatment effect
and menopausal status in the main AZURE study, the numbers
of events are likely insufficient for definitive analysis.
Corresponding continuous (log-transformed) analyses for
bone metastases at any time found no statistically significant
interaction with treatment allocation for any of the markers
analyzed (P1NP: P ¼ .74; CTX: P ¼ .47; 1-CTP: P ¼ .31), confirming
that these baseline markers are not predictive of the treatment
benefits of zoledronate.
Discussion
Our study showed that patients with high serum levels of P1NP,
CTX, or 1-CTP shortly after diagnosis of early breast cancer were
associated with a higher risk of developing bone metastasis dur-
ing the course of their disease. P1NP appeared to be the most
sensitive of the markers studied, but was not predictive of bene-
fit from zoledronate. Using CTX and P1NP as a composite bio-
marker did not add to the sensitivity of the individual markers.
This may be partially because the markers are not independent,
reporting on essentially linked metabolic processes, but may
also be due to the relatively small number of events in the com-
bined group.
It has been long-established that the rate of bone loss accel-
erates relatively rapidly in perimenopause, across the meno-
pausal transition, with consequent increase in bone turnover
markers, associated with an accelerated decrease in measured
bone mineral density (BMD) (14,15). The inverse relationship be-
tween loss of BMD and increase in bone turnover markers (in-
cluding P1NP and CTX) from premenopause through
perimenopause to postmenopause is well established (16). As
anticipated, our data reflect this pattern, with baseline bone
marker values all increasing progressively from premenopause,
through the early years following cessation of menses, to more
than five years postmenopause.
Although all three markers and especially P1NP are good pre-
dictors of bone-specific recurrence, the calculated values of
Harrell’s c-index (each around 0.57) suggest that they have only
low-to-moderate discrimination, although this is statistically dif-
ferent from a chance finding as shown by the lower limit in the
95% confidence intervals being greater than 0.5. From a clinical per-
spective, however, it should be borne in mind that even for the two
key prognostic indicators in everyday use in breast cancer (lymph
nodes and stage), c-indices are 0.62 and 0.63, respectively (W.
Gregory, personal communication), only marginally greater than
those values reported for the three bonemarkers in this study.
Our findings are consistent with a bone microenvironment
with increased bone turnover, providing a fertile “soil” for the
development of skeletal metastasis. By contrast with this clear
association between baseline bone turnover markers and
Table 1. Baseline demographics of patients in the biomarker subpop-
ulation and overall AZURE population*
Parameter
Biomarker
population
Overall study
population
(n ¼ 872) (n ¼ 3359)
No. (%) No. (%)
Mean age, y 51.4 51.5
Lymph node status
0 16 (1.8) 62 (1.8)
1–3 534 (61.2) 2075 (61.8)
4 320 (36.7) 1211 (36.1)
Unknown 2 (0.2) 11 (0.3)
T stage
T1 285 (32.7) 1065 (31.7)
T2 427 (49.0) 1717 (51.1)
T3 131 (15.0) 456 (13.6)
T4 29 (3.3) 117 (3.5)
Histological grade
1 66(7.6) 285 (8.5)
2 361 (41.4) 1439 (42.8)
3 428 (49.1) 1552 (46.2)
ER status
Positive 676 (77.5) 2634 (78.4)
Negative 192 (22.0) 705 (21.0)
Unknown 4 (0.5) 20 (0.6)
PR status
Positive 361 (41.4) 1423 (42.4)
Negative 205 (23.5) 806 (24.0)
Unknown 304 (34.9) 1119 (33.3)
HER2 status
Positive 108 (12.4) 415 (12.4)
Negative 318 (36.5) 1251 (37.2)
Unknown/not measured 442 (50.6) 1672 (49.8)
Neo-adjuvant therapy intended 52 (6.0) 212 (6.3)
Systemic therapy
Endocrine therapy alone 33 (3.8) 152 (4.5)
Chemotherapy alone 190 (21.8) 719 (21.4)
Endocrine therapy and
chemotherapy
649 (74.4) 2488 (74.1)
Use of statins 43 (4.9) 197 (5.9)
Type of chemotherapy
Anthracyclines 819 (93.9) 3132 (93.2)
Taxanes 178 (20.4) 775 (23.1)
Menopausal status
Premenopausal 409 (46.9) 1504 (44.8)
5 y since menopause 123 (14.1) 490 (14.6)
>5 y since menopause 266 (30.5) 1041 (31.0)
Unknown 74 (8.5) 324 (9.6)
*ER ¼ estrogen receptor; HER2 ¼ human epidermal growth factor receptor;
PR ¼ progesterone receptor.
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recurrence in bone, there was no association detectable between
bone turnover markers and distant recurrence taken as a whole,
indicating that bone turnover markers specifically provide prog-
nostic information for future recurrence in bone and not for me-
tastasis more generally (17–19). We acknowledge that, in some
cases, elevation of baseline bone markers may be linked with ac-
tive, but as yet undetected, bone metastases. However, the rela-
tively long follow-up (median ¼ 84 months) and few bone events
in the first two years (<5%), when the cumulative incidence
curves diverge, makes it unlikely that the raised markers are sim-
ply an early diagnostic indication of bonemetastases.
There is important literature evidence supporting our study.
In particular, Lipton et al. (12) investigated b-CTX in 621 postme-
nopausal early breast cancer patients in a five-year phase III
trial of tamoxifen þ/ octreotide. Over 7.9 years (median) of fol-
low-up, 19 (3.1%) patients developed bone-only recurrence as
first event, 47 (7.5%) developed bone and concurrent other re-
lapse as first event, and 57 (9.2%) developed first recurrence in
sites excluding bone. Using a categorical analysis (cut-point ¼
0.71 ng/mL), higher pretreatment b-CTX was associated with
shorter bone-only recurrence-free survival (HR ¼ 2.8, 95% CI ¼
1.05 to 7.48, P ¼ .03). However, there was no statistically
Table 2. Distribution of patients with high/normal bone marker values according to menopausal status*
Biomarker Whole population Premenopausal 0–5 y postmenopausal >5 y postmenopausal
P1NP
Assay, median (IQR), ng/mL 55.1 (41.2–72.7) 49.1 (37.3–64.3) 58.4 (42.8–76.1) 64.8 (48.1–84.4)
No. of patients 867 409 121 263
% > 70 ng/mL 27.3 18.3 30.1 38.7
CTX
Assay, median (IQR), ng/mL 0.23 (0.15–0.32) 0.18 (0.13–0.26) 0.25 (0.18–0.37) 0.29 (0.21–0.41)
No. of patients 863 408 120 262
% > 0.299 ng/mL 30.0 17.4 37.4 45.9
% > 0.556 ng/mL 4.2 1.0 7.3 7.9
1CTP
Assay, median (IQR), ng/mL 4.25 (3.26–5.15) 3.99 (3.12–4.95) 4.26 (3.20–5.02) 4.60 (3.77–5.41)
No. of patients 861 408 118 265
% > 4.2 ng/mL 50.5 44.5 49.6 61.7
*This table does not include data for the patients whose menopausal status was unknown, included in the whole study population. 1-CTP ¼ pyridinoline cross-linked
carboxy-terminal telopeptide of type-1 collagen; CTX ¼ C-telopeptide of type-1 collagen; IQR ¼ interquartile range; P1NP ¼ N-terminal propeptide of type-1 collagen.
Figure 1. Hazard ratios and 95% confidence intervals for adjusted continuous analyses of log-transformed data for baseline N-terminal propeptide of type-1 collagen,
C-telopeptide of type-1 collagen, and pyridinoline cross-linked carboxy-terminal telopeptide of type-1 collagen and disease outcomes. P values were calculated using
the likelihood ratio v2 test statistic, and tests were two-sided. 1-CTP ¼ pyridinoline cross-linked carboxy-terminal telopeptide of type-1 collagen; CI ¼ confidence inter-
val; CTX ¼ C-telopeptide of type-1 collagen; HR ¼ hazard ratio; P1NP ¼ N-terminal propeptide of type-1 collagen.
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significant association with first event in the bone plus concur-
rent relapse elsewhere or with first recurrence at other distant
sites. It should be noted that there were differences in the pa-
tient populations and administration of bone-targeted therapy
between the Lipton et al. study and our data (the former in-
cluded only postmenopausal patients whose tumors were
mostly ER positive with consequent lower-risk disease).
A limitation of our study is that only baseline biomarker
measurements were available, although because the propor-
tional hazards assumption was not violated, this suggests no
difference in the effect of the markers as time elapses. While
our data suggest that the rate of bone turnover at this early
stage of disease when tumor cells may be homing to potential
metastatic sites is a statistically significant contributing factor
to development of bone metastasis, changes in subsequent
bone turnover may also play a role. There is evidence that this
might be the case in a study that assessed paired serum sam-
ples at baseline and one year within a large, placebo-controlled,
randomized study of oral clodronate in early breast cancer (20).
Although baseline P1NP was not prognostic for developing bone
metastasis after five years of follow up, the incidence of bone
metastasis was statistically significantly higher in women
whose P1NP value increased by more than 20% in the first year
(P < .02).
A further possible limitation of our analysis is that the bio-
marker population comprised slightly more than 25% of the total
AZURE population. Although we have shown that both baseline
demographics and outcomes of the biomarker population and
the total trial population are similar, this cannot completely ex-
clude the possibility of bias in the population analyzed.
Because the treatment benefits of adjuvant zoledronate in
postmenopausal women might be related to inhibition of the
increased bone turnover associated with menopause, our find-
ing that baseline P1NP levels were not predictive for benefit
from zoledronate was initially surprising. However, a number of
factors (in addition to low event numbers in some analyses)
may contribute to this result. Administration of multiple doses
of a potent bisphosphonate can confidently be assumed to sup-
press bone turnover throughout the five-year treatment period.
This could render baseline marker values less relevant in analy-
ses of association. Also, it should be noted that, although
zoledronate only produced a benefit in overall invasive relapse
in patients who were five or more years postmenopause, it was
associated with a reduction in first and subsequent metastasis
to bone across all menopausal groups (6). Additionally, bone
turnover markers reflect activity across the skeleton as a whole,
whereas the amount of bone associated with disseminated tu-
mor cells likely comprises only a very small fraction of the total
skeletal metabolic activity. Finally, there is the intriguing possi-
bility that the efficacy of zoledronate in the adjuvant setting
may be due to a direct toxic effect on tumor cells in the bone mi-
croenvironment and independent of its action on bone
turnover.
Other recent studies have also addressed the need for prognos-
tic/predictive biomarkers relating to adjuvant bone-targeted
treatment in early breast cancer. Using primary tumor tissue from
patients in the AZURE study, we showed that a novel composite
biomarker comprising the proteins CAPG and GIPC1was prognostic
for developing bone metastasis (HR ¼ 4.5, 95% CI ¼ 2.1 to 9.8, P <
.001) and predicted response to zoledronate (P ¼ .008) (21).
Table 3. Adjusted analyses for high vs normal values of bone markers and analyses for interquartile range change for continuous analyses
Analysis
Bone marker high
No. of events/
patients (%)
Bone marker normal
No. of events/
patients (%)
Adjusted categorical
analysis
Adjusted continuous
analysis
HR (95% CI) P*
HR for IQR change
(log transformed)
(95% CI)† P*
PINP (70 ng/mL cut-point, n¼ 867)
Bone recurrence at any time 37/238 (15.5) 67/629 (10.7) 1.61 (1.07 to 2.42) .03 1.42 (1.10 to 1.82) .006
First recurrence in bone 29/238 (12.2) 53/629 (8.4) 1.58 (1.00 to 2.50) .06 1.38 (1.04 to 1.84) .03
First distant recurrence (at any site) 54/238 (22.7) 134/629 (21.3) 0.99 (0.72 to 1.37) .96 1.04 (0.87 to 1.24) .64
IDFS 69/238 (29.0) 179/629 (28.5) 0.97 (0.73 to 1.29) .83 1.06 (0.91 to1.25) .43
CTX (0.299 ng/mL cut-point, n¼ 863)
Bone recurrence at any time 40/262 (15.3) 64/601 (10.6) 1.55 (1.05 to 2.31) .03 1.41 (1.09 to 1.82) .009
First recurrence in bone 28/262 (10.7) 54/601 (9.0) 1.27 (0.80 to 2.00) .32 1.29 (0.97 to 1.72) .08
First distant recurrence (at any site) 67/262 (25.6) 121/601 (20.1) 1.26 (0.93 to 1.71) .13 1.11 (0.92 to 1.33) .27
IDFS 87/262 (33.2) 161/601 (26.8) 1.24 (0.96 to 1.62) .11 1.15 (0.99 to 1.35) .08
CTX (0.556 ng/mL cut-point, n¼ 863)
Bone recurrence at any time 7/37 (18.9) 97/826 (11.7) 1.95 (0.90 to 4.21) .12 1.41 (1.09 to 1.82) .009
First recurrence in bone 6/37 (16.2) 76/826 (9.2) 2.17 (0.94 to 5.01) .10 1.29 (0.97 to 1.72) .08
First distant recurrence (at any site) 9/37 (24.3) 179/826 (21.7) 0.94 (0.47 to 1.86) .85 1.11 (0.92 to 1.33) .27
IDFS 14/37 (37.8) 234/826 (28.3) 1.15 (0.66 to 2.00) .62 1.15 (0.99 to 1.35) .08
1-CTP (4.2 ng/mL cut-point, n¼ 861)
Bone recurrence at any time 59/440 (13.4) 45/421 (10.7) 1.39 (0.94 to 2.05) .10 1.43 (1.10 to 1.86) .008
First recurrence in bone 45/440 (10.2) 37/421 (8.8) 1.30 (0.84 to 2.02) .24 1.36 (1.01 to 1.84) .045
First distant recurrence (at any site) 100/440 (22.7) 87/421 (20.7) 1.19 (0.89 to 1.59) .25 1.15 (0.94 to 1.39) .18
IDFS 131/440 (29.8) 116/421 (27.6) 1.18 (0.91 to 1.53) .21 1.20 (1.00 to 1.42) .04
*P values were calculated using the likelihood ratio v2 test statistic, and tests were performed at the two-sided 5% significance level. 1-CTP ¼ pyridinoline cross-linked
carboxy-terminal telopeptide of type-1 collagen; CI ¼ confidence interval; CTX ¼ C-telopeptide of type-1 collagen; HR ¼ hazard ratio; IDFS ¼ invasive disease–free sur-
vival; IQR ¼ interquartile range; P1NP ¼ N-terminal propeptide of type-1 collagen.
†These results show the hazard ratio for an interquartile range increase in the log10 (P1NP) or ln (CTX, 1-CTP) transformed variables. The P value of these analyses is
unchanged from the adjusted continuous analyses shown in Figure 1.
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Figure 2. A) Cumulative incidence function for time to bone metastasis at any time for categorical analysis of N-terminal propeptide of type-1 collagen (P1NP) level 
or<70 ng/mL (hazard ratio [HR] for adjusted analyses ¼ 1.61, 95% confidence interval [CI] ¼ 1.07 to 2.42, P ¼ .03). B) Cumulative incidence function for time to bone me-
tastasis at any time by treatment arm for participants with high P1NP (70 ng/mL; HR for adjusted analyses ¼ 0.989, 95% CI¼0.517 to 1.895, Pinteraction ¼ .69 for the inter-
action between P1NP and treatment; ie, to assess for differing effects of treatment within the two groups of high or normal P1NP). P values were calculated using the
likelihood ratio v2 test statistic, and tests were two-sided. 1-CTP ¼ pyridinoline cross-linked carboxy-terminal telopeptide of type-1 collagen; CTX ¼ C-telopeptide of
type-1 collagen; P1NP ¼ N-terminal propeptide of type-1 collagen; ZOL ¼ zoledronate 4 mg (19 doses over 5 years).
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In another study, amplification of the 16q23 chromosomal region,
including amplification of the MAF gene (22), was predictive of
breast cancer metastasis to bone (23). However, there remains a
need for a simple blood-based test in early breast cancer that can
identify patients with a high risk for development of bonemetasta-
sis. Bone turnover markers are easily measured and are worthy of
additional investigation in helping to meet this need.
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